Tolemy Bio Secures €1.4M to Develop AI-Powered Cell Biology Platform for Therapeutic Manufacturing
核心洞察
Tolemy Bio (搜索) raised €1.4 million in funding led by Norrsken Evolve (搜索) to develop Orbit, an AI-enabled control panel for cell biology experiments.
The platform integrates laboratory data from multiple sources into a single workspace and uses virtual cell models to help scientists optimize cell-based therapeutic development.
Early partnerships include MIT, University of Cambridge, and cell therapy (搜索) organizations, with a focus on improving consistency and manufacturability in cell therapy manufacturing.
Tolemy Bio (搜索), a Cambridge and Barcelona-based biotechnology startup, has secured €1.4 million in pre-seed funding to advance its AI-powered platform designed to streamline cell biology research and therapeutic manufacturing. The round was led by Norrsken Evolve (搜索), with participation from Big Sur Ventures (搜索), JME Ventures (搜索), Masia and a new UK stealth fund.
The funding will support the expansion of Tolemy Bio (搜索)'s data generation, machine learning and engineering capabilities, further development of its core product Orbit, and early deployments with academic and industry partners.
Addressing Cell Biology's Data Intelligence Gap
Tolemy Bio (搜索) is targeting what it describes as a persistent bottleneck in modern biopharma: the difficulty of converting complex cell biology experiments into reliable, reusable intelligence. Cell therapies, therapeutic proteins and other cell-based products often depend on small changes in culture conditions, media composition or process parameters that can significantly impact product quality, consistency and manufacturability.
"During my time working in the lab, it became clear to me that cell biology is still too difficult to interpret, optimize and reproduce," said Alex Ward, co-founder and CEO of Tolemy Bio (搜索). "Teams generate huge amounts of experimental data, but too often that data does not become reusable intelligence. We founded Tolemy Bio to change that."
The Orbit Platform
The company's core product, Orbit, is positioned as an AI-enabled "control panel" for the cell. The platform is designed to integrate data from existing laboratory equipment, spreadsheets, notebooks and shared folders into a single workspace. A second layer combines "virtual cell" models with research agents intended to help scientists understand how living cells respond to environmental changes and guide future experimental decisions.
Orbit has already attracted interest from several prominent organizations, including MIT, the University of Cambridge, MFX and UK charity organization Anthony Nolan (搜索), which are signed up for a phased roll-out.
Strategic Partnerships and Applications
Earlier this year, Tolemy Bio (搜索) partnered with California-based GeminiBio (搜索) to launch aiMOS, an AI-enabled media optimization service for cell therapy (搜索) manufacturing. According to GeminiBio, the service combines AI, machine learning and multi-omics data to design custom media supplements aimed at improving performance, consistency and scalability in cell therapy manufacturing.
The company plans to generate experimental datasets needed to train and validate its virtual cell models through both internal laboratory work and partner data collaborations. This approach is designed to improve how Orbit interprets cell behavior and recommends future experiments.
Market Position and Investment Rationale
Tolemy Bio (搜索) enters a competitive landscape where large pharmaceutical companies are investing heavily in AI for drug discovery and development. The company's strategy focuses on providing smaller and mid-sized biopharma companies access to similar infrastructure without requiring internal development.
Rebecka Löthman Rydå, General Partner at Swedish VC firm Norrsken Evolve (搜索), said the investor was attracted by Tolemy Bio (搜索)'s focus on infrastructure rather than "another AI tool for biopharma." Norrsken Evolve, which closed a €57 million pre-seed fund in 2025, backs early-stage European companies working on resilience and sustainability themes, including biotechnology and health tech.
Company Background
Tolemy Bio (搜索) was founded by Alex Ward and Caelan Anderson, who previously worked together at Australian cultivated meat company Vow (搜索). Their combined backgrounds span cell biology, computational modeling, lab automation, software engineering and cell culture process development. The company describes itself as "the AI-native virtual cell platform for therapeutic development and manufacture."
The team will remain officially based in Cambridge, UK, while largely operating and deploying from Barcelona for the foreseeable future. The commercial challenge ahead will be demonstrating that the platform can move beyond data organization to deliver experimentally validated improvements in cell-based development and manufacturing processes.